In May 2026, At the EASL Congress 2026, MetaVia presented promising late-breaking Phase 1 clinical trial results for DA-1726, an investigational dual GLP-1 and glucagon receptor agonist under development for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
These indicators create an important stop gap to make sure that people are engaging in the most important programs for them
My biggest fear is that so many people will feel like they should take these drugs because they are eating really healthy and they are working out a lot, and they think, If I cant beat themjoin them. How To Run Safely While On A GLP-1 Though its not the right answer for everyone, its possible to take a GLP-1 and pick up, stick to, or even progress in your running
For many vitamins, this oral route is perfectly effective
How to talk to your provider about GLP1 options These are very personalized conversations that need to be had with your physician, Chao says